APRE
APRE clinical trials: Aprea Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Aprea Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 12
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
APRE on the catalyst calendar · APRE registry changes
- Primary completion Jun 2027Sponsor estimatePhase 1NCT06260514Study of APR-1051 in Patients With Advanced Solid TumorsAprea Therapeutics · Advanced Solid TumorRecruitingAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 9, 2026ActualPhase 1/Phase 2NCT04905914Study Of ATRN-119 In Patients With Advanced Solid TumorsAprea Therapeutics · Advanced Solid TumorCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2022ActualPhase 1/Phase 2NCT04383938Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesAprea Therapeutics · Bladder CancerCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2022ActualPhase 1NCT04638309APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)Aprea Therapeutics · MDSTerminatedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2021ActualPhase 1/Phase 2NCT04419389APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)Aprea Therapeutics · Non Hodgkin LymphomaTerminatedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2022ActualPhase 1NCT04214860APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesAprea Therapeutics · Myeloid MalignancyCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 27, 2021ActualPhase 2NCT03931291APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following...Aprea Therapeutics · Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2020ActualPhase 3NCT03745716APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)Aprea Therapeutics · MDSCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 10, 2019ActualPhase 2NCT03268382p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246Aprea Therapeutics · High-grade Serous Ovarian CancerCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2019ActualPhase 1/Phase 2NCT02098343p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination...Aprea Therapeutics · Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53CompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2018ActualPhase 1/Phase 2NCT03391050A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaAprea Therapeutics · MelanomaTerminatedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2010ActualPhase 1NCT00900614Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate CancerAprea Therapeutics · Hematologic NeoplasmsCompletedAPRELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2029Sponsor estimatePhase 1NCT07617363ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSWashington University School of Medicine · Acute Myeloid LeukemiaRecruitingAPRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2030Sponsor estimatePhase 1/Phase 2NCT07578467Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCsAbramson Cancer Center at Penn Medicine · HPV Positive Oropharyngeal Squamous Cell CarcinomaNot yet recruitingAPRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2020ActualPhase 1/Phase 2NCT03588078Study of the Safety and Efficacy of APR-246 in Combination With AzacitidineGroupe Francophone des Myelodysplasies · Myelodysplastic Syndrome With Gene MutationCompletedAPRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2019ActualPhase 1/Phase 2NCT03072043Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsH. Lee Moffitt Cancer Center and Research Institute · Myelodysplastic SyndromeCompletedAPRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner